AMRX vs PG · P/E 44, rev $2.79B vs P/E 25, rev $84.28B
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) versus Procter & Gamble Company (PG) — a side-by-side from cached financials, not a winner call.
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Procter & Gamble Company (PG) is a household & personal products company listed on US. It is led by Jon Moeller.
Latest reported AMRX revenue for 2024-12-31 was $2.79B. Net income was -$73.9M. Revenue was up 16.7% from 2023-12-31 to 2024-12-31. AMRX currently screens at market cap $5.19B and trailing P/E 44.0.
Latest reported PG revenue for 2025-06-30 was $84.28B. Net income was $15.97B. PG currently screens at market cap $373.53B and trailing P/E 25.3.
AMRX currently screens at market cap $5.19B and trailing P/E 44.0. PG currently screens at market cap $373.53B and trailing P/E 25.3.
Not investment advice. Open the AMRX and PG stock pages for the full models.
Not investment advice.